My ePortfolio Register   

Drug resistance mechanisms

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.12.15
Views: 1344
Rating:

Dr Floris Groenendijk - Erasmus Medical Center, Rotterdam, Netherlands

Dr Groenendijk goes through the main points of his talk the 3rd EurocanPlatform Translational Research Course, on resistance to targeted therapies in cancer. He emphasises the need for combination therapies over sequential therapies to maximise treatment effectiveness.

He explores the clinical significance this research could have, especially in terms of increasing overall survival in patients receiving targeted therapies. He gives examples of drug resistance, such as with vemurafenib in melanoma.

He then goes through the next steps this field will take, what obstacles they face and what the eventual benefit will be.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence